Paid Clinical Trials Nashville
Discover 1,238 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Investigational CMV Vaccine Study for Volunteers Ages 9–15Investigational CMV Vaccine Study for Volunteers Ages 9–15
Sponsor:
Moderna
Location:
Code:
NCT05575492
Conditions
Cytomegalovirus
Eligibility Criteria
Sex: All
Age: 9 - 15
Healthy Volunteers: Accepted
Interventions
mRNA-1647
Placebo
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionA Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Sponsor:
Amgen
Location:
Code:
NCT05325866
Conditions
Solid Tumors
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Bemarituzumab
A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Sponsor:
Cytokinetics
Location:
Code:
NCT06412666
Conditions
Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Aficamten
Placebo
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKDSodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
Sponsor:
UCLA
Location:
Code:
NCT04984226
Conditions
Chronic Kidney Diseases
Metabolic Acidosis
Fatigue
Physical Endurance
Insulin Resistance
Eligibility Criteria
Sex: All
Age: 21 - 70+
Healthy Volunteers: Not accepted
Interventions
Sodium bicarbonate
placebo
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer PatientsGastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer Patients
Sponsor:
Vanderbilt University Medical Center
Location:
Code:
NCT00899626
Conditions
Colorectal Cancer
Esophageal Cancer
Gastric Cancer
Pancreatic Cancer
Precancerous Condition
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsA Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Sponsor:
Krystal Biotech, Inc.
Location:
Code:
NCT06228326
Conditions
Lung Cancer, Non-small Cell
Lung Cancer Metastatic
Solid Tumor, Adult
Advanced Cancer
Lung Cancer (NSCLC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KB707
Pembrolizumab (KEYTRUDA®)
Chemotherapy
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaStudy to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Sponsor:
C4 Therapeutics, Inc.
Location:
Code:
NCT04756726
Conditions
Multiple Myeloma
Lymphoma, Non-Hodgkin's
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cemsidomide
Dexamethasone Oral
Primary Subtalar Arthrodesis for Calcaneal FracturesPrimary Subtalar Arthrodesis for Calcaneal Fractures
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06249126
Conditions
Calcaneus Fracture
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)
Open Reduction Internal Fixation (ORIF) only
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSAn Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Sponsor:
XenoPort, Inc.
Location:
Code:
NCT02560766
Conditions
RLS
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
Placebo
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentKRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Sponsor:
Kartos Therapeutics, Inc.
Location:
Code:
NCT03662126
Conditions
Primary Myelofibrosis (PMF)
Post-Polycythemia Vera MF (Post-PV-MF)
Post-Essential Thrombocythemia MF (Post-ET-MF)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KRT-232
Best Available Therapy (BAT)
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate